Proposed and interim European quality specificationsfor imprecisionand inaccuracy have been compared with the US CUA total error criteria for proficiencytesting (PT). To assess the relative demands of separate imprecisionand inaccuracy specificationsvs total error criteria, we derived the imprecision and inaccuracy that would be allowable if a testing process were to provide 90% assurance of achieving the analytical quality required by CLIA PT criteria. Charts of operating specifications (OPSpecs charts) were prepared for commonly used single-rule and multirule quality control procedures with 2 and 4 control measurements per run. Of the 23 tests studied, the proposed European specifications for imprecision and inaccuracy were more demanding than the CLIA requirements for 12 tests (albumin, alkaline phosphatase, amylase, calcium, chloride, creatinine, lactate dehydrogenase, lithium, magnesium, total protein, sodium, and thyroxine). The CLIA total error criteria were more demanding than the proposed European specifications for nine tests (alanine aminotransferase, asparate aminotransferase, total bilirubin, cholesterol, creatine kinase, iron, triglycerides, uric acid, and urea nitrogen). Two tests (glucose, potassium) showed different requirements at different decision levels. Manufacturers and laboratory analysts need to compare these different quality specifications on a test-by-test basis to guide the development, selection, evaluation, and control of laboratory measurement procedures. 
The difficulty in comparing these quality requirements arises in part because they describe different measures of performance.
The proposed and interim European specifications provide performance specifications for individual components of error (imprecision and inaccuracy), whereas the CLIA criteria describe the overall performance (total error) that needs to be achieved in routine operation.
In effect, the European recommendations are specifications for operating a process, whereas the CLIA criteria are outcome criteria. From a laboratory perspective, operating specifications are needed for the imprecision and inaccuracy that are allowable and for the quality control that is necessary to detect errors and assure that a desired total error criterion will not be exceeded (4) . In this context, the two recommendations provide different parts of the overall specifications needed to manage the analytical quality of laboratory testing processes. However, they cannot be compared unless specifications for quality-control (QC) procedures are also considered.
In earlier work, analytical and clinical quality-planning models have been formulated to describe the relations of imprecision, inaccuracy, and QC to the quality requirement that needs to be satisfied (5, 6). Here, we utilize the analytical quality-planning model to facilitate comparison of the European specifications with the CLIA PT criteria for total error.
MaterIals and Methods Proposedand Interim European Specifications
The European working group recommends that the imprecision of a method should be "less than one-half of the average within-subject biological variation, or less than the state of the art achieved by the best 0.20 fractile of laboratories, whichever is the less stringent" (1). The inaccuracy of a method should be "less than onequarter of the group (within-plus between-subject) biological variation, or less than one-sixteenth of the reference interval, when these data do not exist, or less than twice the ideal imprecision, if the above specifications are too demanding" can be used to provide specifications for the allowable inaccuracy and imprecision and for the QC necessary to assure that a criterion for total error is not exceeded in routine operation of a testing process.
Evaluation Procedure
The medical decision levels or target values selected were based on the recommendations of Statland (7) ::
:" Fig. 1 as an imprecision of 3.4%  and a bias of 6.4%) , which is lower than the operating limits for all the commonly used QC procedures. For this test, therefore, the proposed European specifications for inaccuracy and imprecision are more demanding than is needed to assure the performance required by the US CLIA TE criterion of 30%. Figure 2 shows that for cholesterol the proposed European specifications are less demanding than needed to assure the quality required by the CLIA criterion for TE. The operating point is above all the operating limits for the candidate QC procedures, which means that the critical SE value cannot be detected with 90% assurance. Because the operating point is less than the maximum limits for a stable process, the European specifications will provide the quality required by CLIA PT criterion when performance is stable, i.e., as long as Cholesterol operating specifications for providing 90% analytical quality assurance that increases in systematic errors will not cause the CLIA PT criterion of 10% to be exceeded.
Fig. 3. Urea nitrogenoperating specifications for
providing 90% analytical quality assurance that increases in systematic errors will not cause the CLIA PT criterion of 9% to be exceeded. In a few cases (bilirubin, glucose, and uric acid) , the European specifications for imprecision are less than the maximum allowable values, but the inaccuracy causes the operating specifications to be exceeded. If inaccuracy were zero, these specifications for imprecision would satisfy the operating specifications.
